文献速递胸部肿瘤放疗

间质性肺异常对局部晚期非小细胞肺癌同步放化疗后辅助度伐利尤单抗生存的影响

Impact of interstitial lung abnormality on survival after adjuvant durvalumab with chemoradiotherapy for locally advanced non-small cell lung cancer.
PubMed 文献 · Radiother Oncol · 2023-01-11

该研究分析了2018年5月至2021年4月在本机构接受根治性同步放化疗后巩固度伐利尤单抗的113例日本局部晚期非小细胞肺癌患者,中位随访24个月,31例死亡。多因素分析显示,治疗前间质性肺异常评分、腺癌及度伐利尤单抗启动时体能状态与总生存相关。

要点

  • 治疗前间质性肺异常评分、腺癌和度伐利尤单抗启动时体能状态与总生存相关。
  • 间质性肺异常评分和PD-L1 TPS≥1%与病因特异性生存显著相关。
  • PD-L1 TPS≥1%与无进展生存和野内无进展生存显著相关。

核心结论

  • 治疗前间质性肺异常、腺癌和体能状态可能影响接受同步放化疗加度伐利尤单抗的局部晚期非小细胞肺癌患者的总生存。

研究设计与样本

  • 单机构真实世界数据集分析,纳入2018年5月至2021年4月接受根治性同步放化疗和巩固度伐利尤单抗的113例日本局部晚期非小细胞肺癌患者。

主要发现

  • 度伐利尤单抗治疗开始后中位随访24个月(范围5-47个月),31例死亡,其中23例死于肺癌。
  • 多因素分析中与总生存相关的治疗前因素为间质性肺异常评分、腺癌和度伐利尤单抗启动时体能状态。
  • 间质性肺异常评分和PD-L1 TPS≥1%与病因特异性生存显著相关,PD-L1 TPS≥1%与无进展生存和野内无进展生存显著相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Concurrent chemoradiotherapy (CCRT) has been the standard of care for patients with locally advanced non-small cell lung cancer (LA-NSCLC). BACKGROUND AND PURPOSE: The results of the PACIFIC trial established the use of consolidative durvalumab after concurrent chemoradiotherapy (CCRT) as the standard of care for patients with locally advanced non-small cell lung cancer (LA-NSCLC). A subgroup analysis of the PACIFIC trial reported a better progression-free survival (PFS) in Asians. Although real-world data on LA-NSCLC patients who received CCRT plus durvalumab have been reported, there have been few large-scale reports on Asians. In this study, we investigated prognostic factors in the largest real-world data set in Asia of only Japanese LA-NSCLC patients treated with CCRT plus durvalumab. MATERIALS AND METHODS: One hundred and thirteen LA-NSCLC patients who received definitive CCRT and consolidative durvalumab at our institution between May 2018 and April 2021 were analyzed. Overall survival (OS), cause-specific survival (CSS), PFS, distant metastasis-free survival (DMFS), and in-field progression-free survival (IFPFS) were investigated as treatment outcomes using competing risk analyses. RESULTS: During a median follow-up of 24 months (range, 5-47) after the initiation of durvalumab therapy, 31 patients died, of whom 23 died of lung cancer. In the multivariate analysis, the pretreatment factors that correlated with OS were ILA scores, adenocarcinoma, and performance status at the initiation of durvalumab. Furthermore, ILA score and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥ 1 % were significantly correlated with CSS, and PD-L1 TPS ≥ 1 % was significantly correlated with PFS and IFPFS. CONCLUSION: Pretreatment ILA, adenocarcinoma, and performance status may have an impact on OS of LA-NSCLC patients receiving CCRT plus durvalumab.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Kashihara T, Nakayama Y, Okuma K, et al. Impact of interstitial lung abnormality on survival after adjuvant durvalumab with chemoradiotherapy for locally advanced non-small cell lung cancer. Radiother Oncol. 2023. PMID: 36640944. doi:10.1016/j.radonc.2022.109454

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。